Liposomal Doxorubicin Market Growth & Trends
The global liposomal doxorubicin market size is expected to reach USD 1.89 billion by 2030, registering a CAGR of 6.3% from 2024 to 2030. The presence of various pipeline products awaiting approval by the U.S. FDA and European Medicines Agency is one of the key attributes of this market. The first liposomal doxorubicin formulation was launched in 1995, namely Doxil/Caelyx by Janssen Products and LP & Myocet by Teva Pharmaceutical Laboratories. Doxil, the brand name of liposomal doxorubicin, is under development, and post its commercialization, the product is expected to create significant value over the next 3 to 4 years.The increasing U.S. FDA approval for drug production is also anticipated to boost the market. The increasing indication of these drugs for various conditions such as AIDS-related Kaposi sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand. The technological advancements in the drugs formulations to overcome the adverse effects on health and also introduction of various types of medication delivery systems, such as coated nanoparticles, are some of the pivotal factors impelling the demand for the drug.
Liposomal doxorubicin is primarily approved for the treatment of myeloma, Kaposi sarcoma, and ovarian cancer. However, due to its wide usage in other conditions as well, in 2015, breast cancer accounted for the maximum revenue of 21.2%. The increasing prevalence of breast cancer is leading to growing demand for chemotherapy treatment, which accounts for the majority of revenue share. Besides breast carcinoma, ovarian cancer, multiple myeloma, and liver cancer also held a significant share in 2015. The use of doxorubicin for liver carcinoma treatment is rapidly growing, and this application is expected to grow with the fastest CAGR of 7.8% over the forecast period.
Liposomal Doxorubicin Market Report Highlights
- The increasing number of mergers & acquisitions and partnerships for clinical trials on technologically advanced doxorubicin formulations will boost market growth
- Increasing investment in Asia Pacific pertaining to the R&D, improving healthcare infrastructure, and heightened patient cognizance regarding targeted cancer therapies and chemotherapy will drive regional market growth
- The lipodox segment dominated the market with 40.0% share in 2023 and is expected to grow at a CAGR of 7.3% from 2024 to 2030.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Liposomal Doxorubicin Market Variables, Trends, & Scope
Chapter 4. Liposomal Doxorubicin Market: Product Estimates & Trend Analysis
Chapter 5. Liposomal Doxorubicin Market: Application Estimates & Trend Analysis
Chapter 6. Liposomal Doxorubicin Market: Distribution Channel Estimates & Trend Analysis
Chapter 7. Liposomal Doxorubicin Market: Regional Estimates & Trend Analysis
Companies Mentioned
- Sun Pharmaceutical Industries Ltd.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Cipla
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Lupin
- Cadila Pharmaceuticals
- SRS Life Sciences
- GSK plc
- Pfizer Inc.
- Sanofi
- Sigma-Aldrich Co.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 100 |
Published | August 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 1.25 Billion |
Forecasted Market Value ( USD | $ 1.89 Billion |
Compound Annual Growth Rate | 6.3% |
Regions Covered | Global |
No. of Companies Mentioned | 12 |